A new study published by the University of Connecticut in the latest issue of Current Pharmaceutical Design shows that daily use of the telomerase activator TA-65® provided protective effects against metabolic abnormalities associated with Metabolic Syndrome.
This study summarizes the findings on telomere length (TL) changes from a randomized, double blind, placebo controlled study of TA-65 over a 1 year period. The study was conducted on 97 relatively healthy cytomegalovirus-positive subjects aged 53-87 years old.
This human study demonstrates that TA-65MD® nutritional supplements increase telomerase activity and proliferation in human CD4 and CD8 T cells. It highlights the importance of Telomerase Activation in relation to age-associated pathologies.
This animal study looked at the effects of TA-65® and confirmed their mechanism of action, long-term effects, and safety.
In the largest and most diverse study of aging to date, telomere length is being analyzed as a marker for age-related conditions. This genomic project, Genetic Epidemiology Research on Adult Health and Aging (GERA), aims to increase understanding of the genetic basis for a host of problems.
According to a study published in the January 2011 issue of Nature journal, premature aging can be reversed by reactivating telomerase, the enzyme that lengthens telomeres.
